Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursodeoxycholic acid for prevention of relapsing complications after gallstone acute pancreatitis
2024-518237-28-00Phase 4Authorised
- Sponsor
- Hospital General Universitario de Alicante
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute pancreatitis (AP), cholelithiasis, cholangiolitis and 3 more comparing Ursodeoxycholic acid with Placebo (2 arms). Primary endpoint: Composite of death and/or gallstone-related complication. Planned start Oct 2026; status: authorised.
02
Drugs
ursodeoxycholic acid
03
Conditions
acute pancreatitis (AP)cholelithiasischolangiolitischolecystitischoledocholithiasis
Beyond the preview
Go deeper on 2024-518237-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518237-28-00.